{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-010684","form_type":"8-K/A","ticker":"HRMY","cik":"0001802665","company_name":"Harmony Biosciences Holdings, Inc.","filed_at":"2023-05-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.665969+00:00","generated_at":"2026-06-14T10:43:57.199056+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Harmony Biosciences grants CEO Dayno 125,000 options in promotion compensation","bullets":["125,000 options granted under 2020 Incentive Award Plan effective May 26, 2023.","50% of shares vest on May 25, 2025; remainder in 24 monthly installments starting June 25, 2025.","Vesting conditioned on Dr. Dayno's continued service through each vesting date.","Amendment provides details omitted from original April 24, 2023 8-K announcing Dayno's promotion to President and CEO."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-010684","json":"https://secwatch.observer/filing/0001558370-23-010684.json","markdown":"https://secwatch.observer/filing/0001558370-23-010684.md","text":"https://secwatch.observer/filing/0001558370-23-010684.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802665/000155837023010684/0001558370-23-010684-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802665/000155837023010684/hrmy-20230424x8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T10:43:57.199056+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}